ZANTE GREG (Chief Financial Officer) received a stock award from VIKING THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 1/5/2022ACC: 0001209191-22-001988
Officer· Chief Financial Officer
Since Jan 2021
+161.40K
Net shares
Net buyer
$55.9K
Total sold
0
Open market trades
0B · 0S
4
Total transactions
173.33K acquired · 11.93K disposed
Non-Derivative Transactions3
Common Stock, par value $0.00001 per share
Direct
Shares
−3.10K
Price / share
$4.88
Trade value
$15.11K
% of position
3.3%
1/3/2022
94.90K→91.81K
Common Stock, par value $0.00001 per share
Direct
Shares
+53.33K
Price / share
—
Trade value
—
% of position
58.1%
1/3/2022
91.81K→145.14K
Common Stock, par value $0.00001 per share
Direct
Shares
−8.84K
Price / share
$4.62
Trade value
$40.82K
% of position
6.1%
1/4/2022
145.14K→136.30K
Total
Net shares
+41.40K
Net value
-$55.93K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per share Direct | 1/3/2022 | F · Tax Withholding | −3.10K | $4.88 | $15.11K | 3.3% | 94.90K | 91.81K |
| Common Stock, par value $0.00001 per share Direct | 1/3/2022 | A · Award | +53.33K | — | — | 58.1% | 91.81K | 145.14K |
| Common Stock, par value $0.00001 per share Direct | 1/4/2022 | F · Tax Withholding | −8.84K | $4.62 | $40.82K | 6.1% | 145.14K | 136.30K |
| Total | +41.40K | -$55.93K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
120K shares
Shares
+120K
Strike price
4.88
Held after
120K
Exercisable
—
1/3/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock120K shares | 1/3/2022 | A · Award | +120K | 4.88 | — | 120K |